ClinicalTrials.gg
Active, not recruitingNCT06995820Updated Oct 5, 2026

A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.

A Phase 1 interventional study of AZD1613 and Placebo in Healthy, sponsored by AstraZeneca. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Updated Oct 5, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AZD1613 in healthy participants, including Japanese and Chinese descent.

Read the detailed description

This is a first-in-human, randomized, single-blind, placebo-controlled, single and multiple ascending dose study in healthy participants and will be conducted at a single study center. It consists of two parts: Part A (Single Ascending Dose - SAD) and Part B (Multiple Ascending Dose - MAD).

Part A of the study is a SAD sequential group design study and will consist of Parts A1, A2, and A3. Part A1 is planned to consist of 7 cohorts, Part A2 is planned to consist of one cohort of participants of Chinese descent, and Part A3 is planned to consist of 2 cohorts of participants of Japanese descent.

Parts A1, A2, and A3 of the study will comprise of:

  1. A Screening Period of maximum 28 days.
  2. A Treatment Period during which each participant will receive a single subcutaneous (SC) or intravenous (IV) dose of either AZD1613 or placebo on Day 1.
  3. A Follow-up Period where participants will return to the study center for non-residential visits until Day 105.

Part B of the study will be a MAD sequential group design study. Up to 3 dose levels of AZD1613 are planned to be investigated in 3 cohorts of healthy participants.

Part B of the study will comprise of:

  1. A Screening Period of maximum 28 days.
  2. Three Treatment Periods during which participants will receive 3 single subcutaneous (SC) or intravenous (IV) doses of AZD1613 or placebo at 28-day intervals (Day 1, Day 29, and Day 57).
  3. A Follow-up Period where participants will return to the study center for non-residential visits until Day 161.
02

Conditions studied

  • Healthy

Keywords

  • Pharmacokinetics
  • Single ascending dose
  • Multiple ascending dose
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females of non- with suitable veins for cannulation or repeated venipuncture.
  2. Negative pregnancy test at screening and admission (females only).
  3. Females of non-childbearing potential confirmed by status or irreversible surgical sterilization.
  4. Sexually active fertile males must use methods from first administration until 3 months after the last follow-up visit.
  5. (BMI) between 18 and 32 kg/m² and weight at least 50 kg.
  6. Participants of Chinese descent (Part A2) must have both parents and four grandparents who are Chinese.
  7. Participants of Japanese descent (Part A3) must have both parents and four grandparents who are Japanese.

Exclusion criteria

Exclusion Criteria:

  1. The history of any disease or disorder may either put the participant at risk due to participation in the study, influence the results, or affect the participant's ability to participate in the study.
  2. History or presence of gastrointestinal, hepatic, or renal disease affecting drug absorption, distribution, metabolism, or excretion of drugs.
  3. Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of first administration.
  4. Abnormal lab values at screening or admission (e.g., (ALT) > upper limit normal (), aspartate aminotransferase (AST) > ULN, > 1.5 × ULN, estimated (eGFR) \< 80 mL/min/1.73 m², \< lower limit normal [LLN]).
  5. Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results.
  6. Any positive result for serum surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), virus antibody (HCV Ab) or (HIV).
  7. Abnormal vital signs after 5 minutes supine rest at screening or admission (e.g., systolic BP \< 90 mmHg or ≥ 140 mmHg, diastolic BP \< 50 mmHg or ≥ 90 mmHg, heart rate \< 45 or > 85 bpm).
  8. Any clinically important abnormalities in rhythm, conduction, or morphology of resting 12-lead (ECG) at screening or admission (e.g., prolonged > 450 ms, shortened QTcF \< 340 ms, family history of long QT syndrome).
  9. Smokers who smoke more than 5 cigarettes per day and cannot adhere to no smoking during residential visits.
  10. Known or suspected history of alcohol or drug abuse or excessive alcohol intake.
  11. Positive screen for drugs of abuse or alcohol at screening or admission.
  12. History of severe allergy/ or ongoing clinically important allergy/hypersensitivity.
  13. Use of prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, or intake of > 3 × daily recommended levels of vitamins and minerals during the 2 weeks prior to first administration.
  14. Plasma donation within one month of screening or any blood donation/blood loss > 500 mL during the 3 months prior to screening.
  15. Received another new chemical entity within 30 days or 5 half-lives (whichever is longest) of first administration.
  16. Previously received AZD1613.
  17. Involvement in the planning and/or conduct of the study.
  18. Judgment by the Investigator that the participant should not participate due to minor medical complaints or non-compliance with study procedures.
  19. Medical dietary restrictions or inability/unwillingness to comply with meals provided during the stay at the Clinical Unit.
  20. Inability to communicate reliably with the Investigator.
  21. Vulnerable participants (e.g., kept in detention, protected adults under guardianship).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Part A1 (SAD): AZD1613 (Dose 1) SC

    Participants will receive a single dose of AZD1613 (Dose 1) or matching placebo to AZD1613 as SC injection on Day 1.

    Drug: AZD1613 · Drug: Placebo

  • Experimental
    Part A1 (SAD): AZD1613 (Dose 2) SC

    Participants will receive a single dose of AZD1613 (Dose 2) or matching placebo to AZD1613 as SC injection on Day 1.

    Drug: AZD1613 · Drug: Placebo

  • Experimental
    Part A1 (SAD): AZD1613 (Dose 3) SC

    Participants will receive a single dose of AZD1613 (Dose 3) or matching placebo to AZD1613 as SC injection on Day 1.

    Drug: AZD1613 · Drug: Placebo

  • Experimental
    Part A1 (SAD): AZD1613 (Dose 4) SC

    Participants will receive a single dose of AZD1613 (Dose 4) or matching placebo to AZD1613 as SC injection on Day 1.

    Drug: AZD1613 · Drug: Placebo

  • Experimental
    Part A1 (SAD): AZD1613 (Dose 5) IV

    Participants will receive a single dose of AZD1613 (Dose 5) or matching placebo to AZD1613 as an IV infusion on Day 1.

    Drug: AZD1613 · Drug: Placebo

  • Experimental
    Part A1 (SAD): AZD1613 (Dose 6) IV

    Participants will receive a single dose of AZD1613 (Dose 6) or matching placebo to AZD1613 as an IV infusion on Day 1.

    Drug: AZD1613 · Drug: Placebo

  • Experimental
    Part A1 (SAD): AZD1613 (Dose 7) IV

    Participants will receive a single dose of AZD1613 (Dose 7) or matching placebo to AZD1613 as an IV infusion on Day 1.

    Drug: AZD1613 · Drug: Placebo

  • Experimental
    Part A2 (SAD): AZD1613 (Dose 8) IV (Chinese)

    Chinese participants will receive a single dose of AZD1613 (Dose 8) or matching placebo to AZD1613 as an IV infusion on Day 1.

    Drug: AZD1613 · Drug: Placebo

  • Experimental
    Part A3 (SAD): AZD1613 (Dose 9) SC or IV (Japanese)

    Japanese participants will receive a single dose of AZD1613 (Dose 9) or matching placebo to AZD1613 as SC injection or IV infusion on Day 1.

    Drug: AZD1613 · Drug: Placebo

  • Experimental
    Part A3 (SAD): AZD1613 (Dose 10) SC or IV (Japanese)

    Japanese participants will receive a single dose of AZD1613 (Dose 10) or matching placebo to AZD1613 as SC injection or IV infusion on Day 1.

    Drug: AZD1613 · Drug: Placebo

  • Experimental
    Part B (MAD): AZD1613 (Dose 11) SC or IV

    Participants will receive multiple doses of AZD1613 (Dose 11) or matching placebo to AZD1613 as SC injection or IV infusion on Days 1, 29 and 57.

    Drug: AZD1613 · Drug: Placebo

  • Experimental
    Part B (MAD): AZD1613 (Dose 12) IV

    Participants will receive multiple doses of AZD1613 (Dose 12) or matching placebo to AZD1613 as an IV infusion on Days 1, 29 and 57.

    Drug: AZD1613 · Drug: Placebo

  • Experimental
    Part B (MAD): AZD1613 (Dose 13) IV

    Participants will receive multiple doses of AZD1613 (Dose 13) or matching placebo to AZD1613 as an IV infusion on Days 1, 29 and 57.

    Drug: AZD1613 · Drug: Placebo

Interventions

  • DrugAZD1613

    AZD1613 will be administered as either SC injection or IV infusion on Day 1 in Part A and on Days 1, 29 and 57 in Part B of the study.

  • DrugPlacebo

    Placebo will be administered as either SC injection or IV infusion on Day 1 in Part A and Days 1, 29 and 57 in Part B of the study.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) and serious AEs.

    To assess the safety and tolerability of AZD1613 following SC and/or IV administration of single and multiple ascending doses.

    Time frame: AEs: Part A: From Day 1 to Final Follow-up (Day 105); Part B: From Day 1 to Final Follow-up (Day 161); SAEs: Part A: From Screening (Day -28 to Day -2) to Final Follow-up visit (Day 105) Part B: From Screening (Day -28) to Final Follow-up visit (Day 161)

Secondary outcomes

  1. Area under concentration-time curve from time 0 to infinity (AUCinf) (Day 1 only)

    To characterize the single and multiple dose PK of AZD1613 following SC and/or IV administration.

    Time frame: Part A: From Day 1 (pre-dose) to Day 105; Part B: From Day 1 (pre-dose) to Day 141

  2. Area under concentration-time curve from time 0 to the last quantifiable concentration (AUClast)

    To characterize the single and multiple dose PK of AZD1613 following SC and/or IV administration.

    Time frame: Part A: From Day 1 (pre-dose) to Day 105; Part B: From Day 1 (pre-dose) to Day 141

  3. Maximum observed drug concentration (Cmax)

    To characterize the single and multiple dose PK of AZD1613 following SC and/or IV administration.

    Time frame: Part A: From Day 1 (pre-dose) to Day 105; Part B: From Day 1 (pre-dose) to Day 141

  4. Incidence of positive anti-drug antibodies (ADAs) against AZD1613 in serum

    To evaluate the immunogenecity of AZD1613.

    Time frame: Part A: Day 1 (pre-dose), Day 29, Day 57 and Day 105; Part B: Day 1 (pre-dose), Day 29 (pre-dose), Day 57 (pre-dose), Day 85 and Day 161

  5. Change from baseline in study-specific biomarker ABC

    To evaluate target engagement by assessing change in plasma biomarker.

    Time frame: Part A: From Day 1 to Day 105; Part B: From Day -1 to Day 161

07

Study locations

1 site
  • Research Site
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2025 (actual). Primary completion is estimated for Nov 2026, 17 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Sep 2026 → Nov 2026 and completion Sep 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
May 30, 2025
StartActual
Jun 6, 2025
Primary completionEst.
Nov 16, 2026was Sep 2026
CompletionEst.
Nov 16, 2026was Sep 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 5, 2026
Primary completion
Sep 23, 2026→Nov 16, 2026
Oct 5, 2026
Study completion
Sep 23, 2026→Nov 16, 2026
Oct 5, 2026
Enrollment
136 (estimated)→72 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 23, 2026→Nov 16, 2026
    Study completion Sep 23, 2026→Nov 16, 2026
    Enrollment 136 (estimated)→72 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06995820
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
May 30, 2025
Start date
Jun 6, 2025
Primary completion
Nov 16, 2026 (estimated)
Completion
Nov 16, 2026 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion